Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D

In this expert interview at the 22nd Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC), Jennifer B. Green, MD, an endocrinologist and a clinical trialist at Duke University Medical Center, provided updated insight into the implementation of evidence-based therapies for high-risk patients with type 2 diabetes (T2D).

Green highlighted the success of the COORDINATE-Diabetes trial, which aimed to improve the adoption of essential therapies—high-intensity statins, ACE/ARB inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists—in cardiology clinics for patients with T2D and established atherosclerotic cardiovascular disease (ASCVD). The trial showed significant improvements in treatment adherence, addressing a critical gap where only 3-4% of patients were initially receiving all recommended therapies. Green also emphasized the importance of continuing medical education, noting that conferences like these help clinicians stay updated on evolving management strategies, particularly for managing cardio-renal complications in diabetes.

Reflecting on advancements in 2024, Green pointed to the expanding benefits of therapies like GLP-1 receptor agonists and SGLT2 inhibitors, which, beyond managing glucose and weight, are now shown to provide substantial cardiovascular and kidney-related outcomes. She expressed satisfaction in knowing that her prescribing practices are delivering broader benefits than initially expected, reinforcing the importance of implementing the latest evidence to improve patient outcomes.

Disclosures: Relevant disclosures for Green include Bayer, Boehringer Ingelheim, Eli Lilly, Merck, and others.

Reference

Green JB. From Research to Guidelines to Implementing Good Clinical Practice in the Management of Diabetes. Presented at the 22nd Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC). Los Angeles, California. December 12-14, 2024.